- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT03783884
Протокол, сравнивающий временную трансвенозную диафрагмальную стимуляцию со стандартом лечения при отлучении от искусственной вентиляции легких (RESCUE 3)
Рандомизированное, контролируемое, открытое, многоцентровое клиническое исследование для оценки безопасной и эффективной работы системы диафрагмальной кардиостимуляции Lungpacer у пациентов, которым не удалось отучить от искусственной вентиляции легких.
This clinical investigation is an open-label, multi-center, randomized clinical trial (RCT) to demonstrate the safety and effective performance of the Lungpacer DPTS (plus standard of care) as compared to Control (standard of care only) in patients aged 18 years or older who are receiving mechanical ventilation. Eligible Subjects will have received mechanical ventilation for ≥96 hours (4 days) and have failed two weaning attempts.
The goal or outcome is to show a numerically greater proportion of subjects weaned in the Treatment (Lungpacer DPTS) group as compared to the Control group.
Обзор исследования
Статус
Вмешательство/лечение
Подробное описание
The intended patient population is applicable for Lungpacer Diaphragm Pacing Therapy (DPT) because there are no noninvasive alternative treatments for patients who are difficult to wean from MV (i.e., ≥96 hours (4 days) on MV) or who have required prolonged MV (>7 days). The intended patient population includes approximately one-third of all patients on mechanical ventilation. Under standard of care, approximately 50% of these patients will recover from mechanical ventilation (Jung, 2016). Standard of care involves daily weaning attempts, known as Spontaneous Breathing Trials (SBTs) or Ventilator Liberation Trials (VLTs) that are intended to encourage diaphragm use and strengthening over time.Therefore, Lungpacer DPT efficacy evaluation must be compared to standard of care in a Control group. Lack of recovery from mechanical ventilation may be due to the inability of a patient to participate in VLTs or weaning attempts, due to extensive diaphragm weakness or sedation, the inability of VLTs to induce sufficient diaphragm strengthening, or co-morbidities that prevent recovery.
Тип исследования
Регистрация (Действительный)
Фаза
- Непригодный
Контакты и местонахождение
Места учебы
-
-
-
Berlin, Германия, 10117
- Berlin Charite Mitte
-
Essen, Германия, 45276
- KEM Essen
-
Löwenstein, Германия, 74245
- SLK Löwenstein
-
Nuremberg, Германия, 90419
- Nürnberg Klinikum Nord
-
Schmallenberg, Германия, 57392
- FKKG Schmallenberg
-
Solingen, Германия, 42699
- Solingen Krankenhaus Bethanien
-
-
Mecklenburg-Vorpommern
-
Greifswald, Mecklenburg-Vorpommern, Германия, 17475
- Universitätsmedizin Greifswald
-
-
-
-
California
-
Stanford, California, Соединенные Штаты, 94305
- Stanford University Medical Center
-
-
Colorado
-
Aurora, Colorado, Соединенные Штаты, 80045
- University of Colorado Anschutz Medical Campus
-
-
Florida
-
Gainesville, Florida, Соединенные Штаты, 32610
- University of Florida, Shands
-
-
Illinois
-
Chicago, Illinois, Соединенные Штаты, 60612
- Rush University Medical Center
-
Chicago, Illinois, Соединенные Штаты, 60611
- Northwestern University Feinberg School of Medicine
-
Chicago, Illinois, Соединенные Штаты, 60612
- U of Illinois at Chicago
-
Hines, Illinois, Соединенные Штаты, 60141
- Edward Hines VA Hospital
-
Maywood, Illinois, Соединенные Штаты, 60153
- Loyola University Medical Center
-
-
Indiana
-
Indianapolis, Indiana, Соединенные Штаты, 46202
- Indiana University Health Methodist Hospital
-
-
Kentucky
-
Louisville, Kentucky, Соединенные Штаты, 40202
- University of Louisville
-
-
Massachusetts
-
Burlington, Massachusetts, Соединенные Штаты, 01805
- Lahey Hospital and Medical Center
-
-
Minnesota
-
Minneapolis, Minnesota, Соединенные Штаты, 55407
- Minneapolis Heart Institute Foundation
-
-
Nebraska
-
Omaha, Nebraska, Соединенные Штаты, 68124
- CHI Health Creighton University Medical Center - Bergan Mercy
-
-
New Jersey
-
Englewood, New Jersey, Соединенные Штаты, 07631
- Englewood Hospital Medical Center
-
-
Ohio
-
Cincinnati, Ohio, Соединенные Штаты, 45267
- University of Cincinnati
-
Cleveland, Ohio, Соединенные Штаты, 44195
- Cleveland Clinic Foundation
-
Columbus, Ohio, Соединенные Штаты, 43210
- Ohio State University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Соединенные Штаты, 19140
- Temple University Hospital
-
-
Rhode Island
-
Warwick, Rhode Island, Соединенные Штаты, 02886
- Kent County Memorial Hospital
-
-
South Carolina
-
Columbia, South Carolina, Соединенные Штаты, 29203
- Prisma Health Baptist Hospital
-
-
Texas
-
Dallas, Texas, Соединенные Штаты, 75390
- University of Texas Southwestern, Zale Lipshy Hospital
-
-
Utah
-
Salt Lake City, Utah, Соединенные Штаты, 84132
- University of Utah
-
-
-
-
-
Angers, Франция, 49933
- CHU Angers
-
Montpellier, Франция, 34295
- CHU Montpellier
-
Paris, Франция, 75651
- Hôpital La Pitié-Salpêtrière
-
Strasbourg, Франция, 67091
- CHU Strasbourg
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Are 18 years or older, and,
- Have been mechanically ventilated for ≥96 hours (4 days), and,
- Have satisfied the Readiness-to-Wean criteria, and,
- Have failed at least 2 weaning attempts (that were conducted at least 48 hours after initiation of MV, and, that were conducted on different calendar days, and, at least one of which was the protocol-specific Ventilator Liberation Trial).
Exclusion Criteria:
- Maximal Inspiratory Pressure (MIP) (absolute value) >50 cm H2O;
- Invasive mechanical ventilation >90 days;
- Currently on extracorporeal membrane oxygenation (ECMO);
- Weaning failure due to hypervolemia;
- Medical history (including imaging) or known anatomy that prevents percutaneous insertion of the Catheter into the intended thoracic vein on the left side.
- Clinically overt congestive heart failure that is preventing weaning;
- Currently being treated with neuromuscular blockade;
- Pre-existing neurological, neuromuscular or muscular disorder that could affect the respiratory muscles;
- Pre-existing severe chronic pulmonary fibrosis;
- Pleural effusions occupying greater than one third of the pleural space on either side;
- BMI >45 kg/m2;
- Known or suspected phrenic nerve paralysis;
- Any electrical device (implanted or external) that may be prone to interaction with, or interference from the Lungpacer DPTS including neurological pacing/stimulator devices, cardiac pacemakers and defibrillators;
- Current hemodynamic instability, sepsis or septic shock;
- Prior bacteremia reported within the last 48 hours;
- Anticipating withdrawal of life support and/or shift to palliation as the goal of care;
- Known or suspected to be pregnant or lactating;
- Currently being treated in another clinical trial studying an experimental treatment that could affect the study primary outcome.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Активный компаратор: Treatment
Subject receives Lungpacer Catheter for transvenous phrenic nerve stimulation to deliver Diaphragm Pacing Therapy Sessions. DPT sessions are 6 sets of 10, delivered twice daily, for a total of 120 stimulation reps per day, plus standard of care for weaning from mechanical ventilation. |
Transvenous phrenic nerve stimulation to induce diaphragm contraction.
Другие имена:
|
|
Без вмешательства: Control
Subject does not receive Lungpacer Catheter or DPT. Subject receives only Standard of care for weaning from mechanical ventilation. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Successful Weaning
Временное ограничение: Through Day 30
|
Cumulative percentage of subjects successfully weaned by Day 30. |
Through Day 30
|
|
Adverse Event Profile
Временное ограничение: 30 days
|
Characterize the adverse event profile to support an observed consistent risk profile for subjects randomized to Treatment compared to subjects randomized to Control. Percentage of subjects with adverse events (AE) and serious adverse events (SAE) were summarized for the Treatment group and the Control group by system organ class (SOC) and lower level term. No formal statistical hypothesis test or criterion for the primary safety endpoint was defined. |
30 days
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Days on Mechanical Ventilation (MV)
Временное ограничение: Successful weaning or Day 30
|
The average days on mechanical ventilation from Day 1 to removal from MV associated with successful weaning or Day 30, whichever comes first, will be statistically significantly smaller for subjects randomized to Treatment as compared to subjects randomized to Control. |
Successful weaning or Day 30
|
|
Maximal Inspiratory Pressure (MIP) Change
Временное ограничение: Baseline last available measure through Day 30.
|
The mean improvement in inspiratory muscle strength as shown by the change in Maximal Inspiratory Pressure (MIP) from randomization to last available measure in subjects randomized to Treatment is superior to that in subjects randomized to Control. |
Baseline last available measure through Day 30.
|
|
Rapid Shallow Breathing Index (RSBI) Change
Временное ограничение: Baseline to last available measure through Day 30.
|
To determine change in Rapid Shallow Breathing Index (RSBI) from randomization to last available measure in subjects randomized to Treatment as compared to Control. RSBI measures the ratio of the respiratory rate to Tidal Volume in breaths/min/L and is commonly used as an index for weaning success. A reduction in RSBI is considered as clinical improvement. |
Baseline to last available measure through Day 30.
|
|
Survival
Временное ограничение: 30 days
|
Cumulative percentage of subjects who survived through Day 30. |
30 days
|
Другие показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Re-instatements of MV (After Successful Weaning) Through Day 30.
Временное ограничение: Through Day 30.
|
Assessment of re-instatements of MV in subjects who were successful weaned through Day 30 in the Treatment group as compared to the Control group. |
Through Day 30.
|
|
Tracheotomy After Randomization
Временное ограничение: Through 30 days
|
Assessment of percentage of subjects after randomization to Day 30 that required tracheostomy in the Treatment group as compared to the Control group. |
Through 30 days
|
|
ICU Discharges to Day 30.
Временное ограничение: through 30 days
|
Assessment of ICU discharges to Day 30 in the Treatment group as compared to the Control group. |
through 30 days
|
|
Hospital Discharges to Day 30.
Временное ограничение: through 30 days
|
Assessment of hospital admissions and discharges to Day 30 in the Treatment group as compared to the Control group. |
through 30 days
|
Соавторы и исследователи
Спонсор
Публикации и полезные ссылки
Полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Действительный)
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- P-300
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
Only investigators participating in this clinical trial will be able to see final de-identified participant data at the completion of the study.
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .